In Q1 of fiscal 2025, the quarter ended Sep 30, 2024, Renalytix plc reported revenue of $522,000, up 13.7% from the same quarter a year earlier. It recorded a net loss of $4.7 million. The operating loss came to $4.1 million, an operating margin of -784.1%. Diluted earnings per share were -$0.04.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2024
|
Q1 FY2025
Sep 30, 2024
|
Q4 FY2024
Jun 30, 2024
|
Q3 FY2024
Mar 31, 2024
|
Q2 FY2024
Dec 31, 2023
|
Q1 FY2024
Sep 30, 2023
|
|---|---|---|---|---|---|---|
| Revenue |
2
|
1
+13.7%
|
1
|
1
|
1
|
0
|
| Cost of revenue |
2
|
0
-15.9%
|
1
|
1
|
0
|
1
|
| Gross profit |
0
|
0
+332.6%
|
0
|
-0
|
0
|
-0
|
| Selling, general and administrative |
17
|
3
-46.0%
|
4
|
4
|
5
|
6
|
| Operating income |
-25
|
-4
+54.0%
|
-6
|
-7
|
-9
|
-9
|
| Pretax income |
-28
|
-5
+53.5%
|
-7
|
-8
|
-8
|
-10
|
| Income tax |
0
|
0
|
0
|
0
|
0
|
0
|
| Net income |
-28
|
-5
+53.4%
|
-7
|
-8
|
-8
|
-10
|
| Basic EPS |
-0.25
|
-0.04
+63.6%
|
-0.05
|
-0.08
|
-0.09
|
-0.11
|
| Diluted EPS |
-0.25
|
-0.04
+63.6%
|
-0.05
|
-0.08
|
-0.09
|
-0.11
|
| Weighted average shares, basic |
111
|
106
+11.5%
|
138
|
98
|
97
|
95
|
| Weighted average shares, diluted |
111
|
106
+11.5%
|
138
|
98
|
97
|
95
|
| Other measures | ||||||
| Depreciation and amortization |
0
|
0
-52.8%
|
0
|
0
|
0
|
0
|
| EBITDA |
-25
|
-4
+54.0%
|
-5
|
-6
|
-9
|
-9
|
| Margins | ||||||
| Gross margin |
12.71%
|
19.16%
|
6.14%
|
-12.34%
|
32.30%
|
-9.37%
|
| Operating margin |
-1,054.93%
|
-784.10%
|
-942.83%
|
-1,224.86%
|
-1,218.76%
|
-1,936.60%
|
| Pretax margin |
-1,191.50%
|
-905.36%
|
-1,207.17%
|
-1,447.29%
|
-1,196.19%
|
-2,212.20%
|
| Profit margin |
-1,191.75%
|
-905.75%
|
-1,207.17%
|
-1,447.29%
|
-1,196.76%
|
-2,212.20%
|
| EBITDA margin |
-1,042.30%
|
-772.61%
|
-932.59%
|
-1,211.96%
|
-1,203.53%
|
-1,908.93%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- RNLXY (OTC), RENXF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- United Kingdom
- Headquarters
- London
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1811115
- Former names
- Renalytix AI plc (until Jun 25, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.